Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relacorilant - Corcept Therapeutics

Next Previous
Drug Profile

Relacorilant - Corcept Therapeutics

Alternative Names: CORT-125134

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Class Antineoplastics; Fluorine compounds; Isoquinolines; Ketones; Organic sulfur compounds; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cushing syndrome; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
  • Phase II Prostate cancer
  • Phase I/II Solid tumours
  • No development reported Adrenocortical carcinoma

Most Recent Events

  • 08 Apr 2024 Corcept Therapeutics completes enrolment in its phase III ROSELLA trial for Peritoneal cancer, Fallopian tube cancer and Ovarian cancer (Late-stage disease, Second-line or greater, Recurrent, Combination therapy) in USA, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, South Korea, Poland, Spain, United kingdom (NCT05257408)
  • 01 Apr 2024 Corcept Therapeutics completes the enrolment in the phase III GRADIENT trial for Cushing syndrome in Austria, Bulgaria, Israel, Italy, Poland, Romania, Spain and Germany (PO) (NCT04308590) (EudraCT2019-004956-12)
  • 12 Jan 2024 Corcept Therapeutics completes a phase I clinical trial in Adenocarcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (PO) (NCT04373265)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top